Qrons Inc. Stock

QRON

US74737F1012

Biotechnology & Medical Research

Market Closed - OTC Markets 09:30:00 2026-05-27 EDT			5-day change	1st Jan Change
0.0111 ^USD	-0.89%		-.--%	-63.00%

08-18	Qrons, Inc.'s Subsidiary First Person Enters Its Next Phase of Growth Following Early Think Fast? Momentum	CI
25-04-16	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Qrons Inc. is a biotechnology company. The Company is focuses on developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria. It has developed a treatment that integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable implant, smart materials, and a novel delivery system. The Company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company researches in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
QRON Stock

As early as today, start finding the best investment opportunities!

08-18	Qrons, Inc.'s Subsidiary First Person Enters Its Next Phase of Growth Following Early Think Fast? Momentum	CI
25-04-16	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-16	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-26	First Person Ltd. completed the acquisition of Qrons Inc. from Jonah Meer, CubeSquare, LLC, Ido Merfeld and others in a reverse merger transaction.	CI
24-11-08	Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-21	First Person Ltd. signed a letter of intent to acquire Qrons Inc. in a reverse merger transaction.	CI
24-08-16	Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-15	Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-15	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-14	Qrons Inc. Auditor Raises 'Going Concern' Doubt	CI
23-11-14	Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-14	Qrons Inc. Announces the Filing of A Provisional Patent Application in Furtherance of Its Neuronal and Infectious Disease Treatments Development, Including Sepsis	CI
23-08-14	Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

23-11-06	Qrons : Change in Certifying Accountants - Form 8-K	PU
23-03-31	QRONS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-11-14	QRONS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-08-15	QRONS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
22-05-16	QRONS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

3 years	0.01	0.12
5 years	0.01	0.12
10 years	0.01	0.12

Manager	Title	Age	Since
Cory J. Rosenberg CEO	Chief Executive Officer	46	2025-02-03
Gail D. Hamilton Azodo CTO	Chief Tech/Sci/R&D Officer	41	2025-02-03
Roseman J. Nemorin CTO	Chief Tech/Sci/R&D Officer	45	2025-02-03

Director	Title	Age	Since
Cory J. Rosenberg BRD	Director/Board Member	46	2025-02-03
Chris L. Claussen BRD	Director/Board Member	55	2025-02-03
Ariel Fainsod BRD	Director/Board Member	45	2025-02-03

Qrons Inc. Stock

Stocks

QRON

US74737F1012

Biotechnology & Medical Research

Chart: Qrons Inc.

Latest news : Qrons Inc.

Press Releases : Qrons Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Qrons Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/22/22	Jonah Meer	Free	Chief Executive Officer	325,000	2.4455%
12/22/22	Ido Merfeld	Free	Founder	325,000	2.4455%
12/22/21	Ido Merfeld	Free	Founder	325,000	2.4455%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
QRONS INC.	-0.89%	-.--%	-	-	575K
LONZA GROUP AG	-0.24%	0.00%	+2.34%	+23.20%	50.96B
REVOLUTION MEDICINES, INC.	+1.92%	+0.36%	+477.97%	+550.09%	46.18B
BEONE MEDICINES AG	-0.15%	-0.28%	+21.65%	+89.41%	42.73B
IQVIA HOLDINGS INC.	+0.81%	+4.91%	+39.28%	+19.41%	43.04B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	33.48B
MEDPACE HOLDINGS, INC.	+0.81%	+1.77%	+31.91%	+138.26%	17.28B
ASCENDIS PHARMA A/S	-1.08%	-3.61%	-	-	16.43B
EUROFINS SCIENTIFIC SE	-0.30%	-0.25%	+11.48%	+28.25%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.85%	+1.76%	+80.26%	+47.26%	14.09B
Average	-0.45%	+1.20%	+84.89%	+118.42%	27.89B
Weighted average by Cap.	-0.36%	+1.16%	+103.37%	+138.80%

	2021	2022
Net sales	-	4.33 3.72 3.49 3.19 6.02 413.37 6.05 41.32 16.01 208.54 16.27 15.92 690.72
Net income	-3.19M -2.74M -2.57M -2.34M -4.43M -304M -4.45M -30.38M -11.77M -153M -11.97M -11.71M -508M	-5.39M -4.63M -4.34M -3.97M -7.49M -514M -7.52M -51.42M -19.93M -260M -20.25M -19.81M -860M
Net Debt	-	-

1 day	-0.89%
Current month	-63.00%
Current year	-63.00%